Fondazione IRCCS Istituto Nazionale dei Tumori — Milan

Public research footprint of Fondazione IRCCS Istituto Nazionale dei Tumori, compiled from the ClinicalTrials.gov public registry.

586

Registered studies

308

Active

181

Recruiting now

195

Completed

Stopped or withdrawn

Most-studied conditions

Non-small Cell Lung Cancer · Breast Neoplasms · Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Carcinoma, Non-Small-Cell Lung

Recently updated registry entries

NCT06203210 — A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With… (Recruiting)
NCT04613596 — Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase… (Recruiting)
NCT06330064 — A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Fondazione IRCCS Istituto Nazionale dei Tumori?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.